Effects of 12 weeks resistant training on MTNR1B gene expression in the pancreas and glucose and insulin levels in type 2 diabetic rats

authors:

avatar rahman soori , * , avatar Mohammad Rashidi , avatar Sirous Choobineh , avatar Ali Asghar Ravasi , avatar Kazem Baesi , avatar A. li Rashidy-Pour

Koomesh: Vol.19, issue 1; 46-55
published online: March 28, 2017
article type: Research Article
received: January 02, 2016
accepted: September 01, 2016

how to cite: soori R, Rashidi M, Choobineh S, Ravasi A A, Baesi K, et al. Effects of 12 weeks resistant training on MTNR1B gene expression in the pancreas and glucose and insulin levels in type 2 diabetic rats. koomesh. 2017;19(1):e151108. 

Abstract

Introduction: Type 2 diabetes is a multifactorial disease, but recently it has been found that increased expression of MTNR1B gene is associated with of the risk of type 2 diabetes. The aim of this study was to evaluate the effect of 12 weeks of resistance training on MTNR1B gene expression in the pancreas and glucose and insulin levels in male Wistar rats with type 2 diabetes. Materials and Methods: This study was a fundamental and experimental approach. In this study 30 male Wistar rats weighing 220±20 g, were used. Rats were kept under the standard conditions of temperature of 22 °±2   C and humidity of 45% and consecutive 12-hour periods of light and darkness. Rats were divided into three groups: Control group, diabetic group, and diabetic plus resistant training group. Diabetes was induced by disolving nicotinamide and STZ in the drinking water. Resistance training was conducted for 12 weeks, 5 days a week in a 3 course with 6 repetitions. All rats were sacrificed 48 hours after the last training session. Results: A significant reduction in fasting glucose levels was observed in the diabetic resistant training group than the diabetic group (P

References

  • 1.

    World Health Organization/Monthly Newsletter of the PAHO/WHO Chronic Disease Program. Chronic Disease Prevention and Control in the Americas. Pan American: WHO, 2008. Available From: URL: http://www.paho.org/English/AD/DPC/NC/dia-wdd- 2008.htm (Diabetes: PAHO urges fight against obesity and malnutrition in the Americas).

  • 2.

    Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006; 1084: 1-29.

  • 3.

    Da Silva Xavier GQ, Cullen PJ, Rutter GA. Distinct roles for insulin and insulin-like growth factor-1 receptors in pancreatic beta-cell glucose sensing revealed by RNA silencing. Biochem J 2004; 377: 149-158.

  • 4.

    Ogino J, Sakurai K, Yoshiwara K, Suzuki Y, Ishizuka N, Seki N, et al. Insulin resistance and increased pancreatic beta-cell proliferation in mice expressing a mutant insulin receptor (P1195L). J Endocrinol 2006; 3: 739-747.

  • 5.

    Yaghootkar, Frayling. Recent progress in the use of genetics to understand links between type 2 diabetes and related metabolic traits. Genome Biol 2013; 14: 203.

  • 6.

    Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009; 41: 77-81.

  • 7.

    Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spgel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired earlyinsulin secretion. Nat Genet 2009; 41: 82-88.

  • 8.

    Bonnefond A, Clment N, Fawcett K, Yengo L, Vaillant E, Guillaume JL, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44: 297-301.

  • 9.

    Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116.

  • 10.

    McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep 2009; 9: 164-171.

  • 11.

    Oxford Centre for Diabetes, Endocrinology and Metabolism / Annual Report 2008/09.

  • 12.

    Ciaran J, McMullan, et al. Melatonin Secretion and the Incidence of Type 2 Diabetes. JAMA 2013; 309.

  • 13.

    Ciaran J, McMullan, et al. Low Levels of Melatonin Up Risk for Type 2 Diabetes. JAMA 2013.

  • 14.

    Xia Q, Chen ZX, Wang YC, Ma YS, Zhang F, Che W, et al. Association between the Melatonin Receptor 1B Gene Polymorphism on the Risk of Type 2 Diabetes, Impaired Glucose Regulation: A Meta-Analysis. PLoS ONE 2012; 7: e50107.

  • 15.

    Cockram CS. The epidemiology of diabetes mellitus in the Asia-Pacic region. Hong Kong. Med J 2000; 6: 43-52.

  • 16.

    The Expert Panel in Korean Medical Insurance Association. 1992 Annuals for Medical Insurance Statistics. Seoul, Korea. Ministry of Health and Welfare 1995.

  • 17.

    Min HK. Noninsulin-dependent diabetes mellitus (NIDDM) in Korea. Diabet Med 1996; 13: 13-15.

  • 18.

    Spars T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, Wegner L, et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes 2009; 58: 1450-1456.

  • 19.

    Salman M, Dasgupta S, Cholendra A, Venugopal PN, Lakshmi GL, Xaviour D, et al. MTNR1B gene polymorphisms and susceptibility to Type 2 Diabetes: A pilot study in South Indians. Gene 2015; 566: 189-193.

  • 20.

    Staiger H, Machicao F, Schfer SA, Kirchhoff K, Kantartzis K, Guthoff M, et al. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One 2008; 3.

  • 21.

    Chambers JC, Zhang W, Zabaneh D, Sehmi J, Jain P, McCarthy MI, et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. Diabetes 2009; 58: 2703-2708.

  • 22.

    Stewart KJ. Exercise training: can it improve cardiovascular health in patients with type 2 diabetes? Br J Sports Med 2004; 38: 250-252.

  • 23.

    Alam S, Stolinski M, Pentecost C, Boroujerdi MA, Jones RH, Sonksen PH. The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinal Metab 2004; 89: 688-691.

  • 24.

    Arora E, Shenoy S, Sandhu JS. Effects of resistance training on metabolic profile of adults with type 2 diabetes. Indian J Med Res 2009; 129: 515-519.

  • 25.

    Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2009; 83: 157-175.

  • 26.

    Grntved A, Pan A, Mekary RA, Stampfer M, Willett WC, Manson JE, et al. Muscle-strengthening and conditioning activities and risk of type 2 diabetes: a prospective study in two cohorts of US women. PLoS Med 2014; 11: e1001587.

  • 27.

    Dugan JA. Exercise recommendations for patients with type 2 diabetes. JAAPA 2016; 29: 13-18.

  • 28.

    Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33: e147-e67.

  • 29.

    Centers for Disease Control and Prevention. National Diabetes Statistics Report 2015.www.cdc.gov/diabetes/data/national.html.

  • 30.

    Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care 2007; 30: 203-209.

  • 31.

    Riebe D, Franklin BA, Thompson PD, Garber CE, Whitfield GP, Magal M, et al. Updating ACSM's Recommendations for Exercise Preparticipation Health Screening. Med Sci Sports Exerc 2015; 47: 2473-2479.

  • 32.

    Hajihasani A, Bahrpeyma F, Bakhtiari AH, Taghikhani M. Effects of eccentric and concentric exercises on some blood biochemical parameters in patients with type 2 diabetes. Koomesh 2012; 13: 338-344. (Persian).

  • 33.

    Shamsi M, Hassanzadeh A, Kachoyee A, Sharifirad G. Influence of walking training on haemoglobin glucosile and fasting blood sugar levels in women with type 2 diabetes. Koomesh 2010; 11: 99-106. (Persian).

  • 34.

    Albright A, Franz M, Hornsby G, Kriska A, Marrero D, Ullrich I, et al. American college of sports medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345-1360.

  • 35.

    Geidl W, Pfeifer K. Physical activity and exercise for rehabilitation of type 2 diabetes. Rehabilitation 2011; 50: 255-265.

  • 36.

    Armstrong MJ, Sigal RJ. Exercise as medicine: key concepts in discussing physical activity with patients who have type 2 diabetes. Can J Diabetes 2015; S1499-2671: 747-749.

  • 37.

    Yang Z, Scott CA, Mao C, Tang J, Farmer AJ. Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 2014; 44: 487-499.

  • 38.

    Sigal RJ, Kenny GP, Boul NG, Wells GA, Prud'homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 18: 357-369.

  • 39.

    Pierre W, Gildas AJ, Ulrich MC, Modeste WN, Benoit NT, Albert K. Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide streptozotocin-induced type 2 diabetic rats. BMC Complement Altern Med 2012; 12: 264-269.

  • 40.

    Shirwaikar A, Rajendran K, Barik R. Effect of aqueous bark extract of Garuga pinnata Roxb. in streptozotocin-nicotinamide induced type-II diabetes mellitus. Ethnopharmacol 2006; 107: 285-290.

  • 41.

    Hu C, Zhang R, Wang C, Yu W, Lu J, Ma X, et al. Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. PLoS One 2010; 23: e11761.

  • 42.

    Li C, Qiao B, Zhan Y, Peng W, Chen ZJ, Sun L, et al. Association between genetic variations in MTNR1A and MTNR1B genes and gestational diabetes mellitus in Han Chinese women. Gynecol Obstet Invest 2013; 76: 221-227.

  • 43.

    Liao S, Liu Y, Tan Y, Gan L, Mei J, Song W, et al. Association of genetic variants of melatonin receptor 1B with gestational plasma glucose level and risk of glucose intolerance in pregnant Chinese women. PLoS One 2012; 7: e40113.

  • 44.

    Semiz S, Dujic T, Velija-Asimi Z, Prnjavorac B, Bego T, Ostanek B, et al. Effects of melatonin receptor 1B gene variation on glucose control in population from Bosnia and Herzegovina. Exp Clin Endocrinol Diabetes 2014; 122: 350-355.

  • 45.

    She M, Laudon M, Yin W. Melatonin receptors in diabetes: a potential new therapeutical target? Eur J Pharmacol 2014; 5: 220-223.

  • 46.

    Bouatia-Naji N, Bonnefond A, Cavalcanti-Proena C, Spars T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009; 41: 89-94.

  • 47.

    Rnn T, Wen J, Yang Z, Lu B, Du Y, Groop L, et al. A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 2009; 52: 830-833.

  • 48.

    Kim JY, Cheong HS, Park BL, Baik SH, Park S, Lee SW, et al. Melatonin receptor 1 B polymorphisms associated with the risk of gestational diabetes mellitus. BMC Med Genet 2011; 10: 82.

  • 49.

    Bonnefond A1, Clment N, Fawcett K, Yengo L, Vaillant E, Guillaume JL, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44: 297-301##.